Client News
MagForce AG announces successful capital increase of the subsidiary MagForce USA, Inc.
31st December 2019
Expedeon shareholders approve sale of proteomics & immunotherapy business and name change to 4basebio AG
19th December 2019
Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial
18th December 2019
Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
18th December 2019
Lindis Blood Care GmbH: Over 5 million euros for Lindis Blood Care – development of a new product for the removal of tumor cells from surgical blood
11th December 2019
SYNIMMUNE GmbH Reports Interim Results of First-in-Human Study of Fc-Optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia
10th December 2019
Motif Bio plc: Confirmation of timing of voluntary delisting from the NASDAQ Capital Market
10th December 2019
Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting
9th December 2019
There is no more content to load